Member Info for Investmaster

I don't disagree.

Interesting we've not been tipped yet as a potential high flyer.

For clarity - all trades today have been buys

HAHAHAHhahahaha....

Chancer....

Bid over 21 so next leg up this afternoon

And breakeven we have..we should end up with a gain today.

And up we are again..expect another rise.

And up we are again..expect another rise.

Bid 20.3

There's an opportunity for the directors to show the wider market confidence in RUA.

I hope they take this moment.

Some of the knowledgeable contributors on the ADVFN site give you a great insight into this business and its huge potential, which has already started.

Worth a read.

This had to happen...new directors now named in companies house. And so it begins -At pace!

The real bid is 20.3p but for some reason the market makers are playing silly buggers...so bid and ask is almost exactly the same !

The SP has taken a dip and profit taking had to happen. The updated news from management seems to support current levels. RSI would seem to indicate a move up again.

Next leg up-

I saw this on Advfn this morning and I totally agree with the sentiment.

gac14114 May '26 - 08:18 - 4569 of 4569 Edit

2 0

I've said it already but I feel it's worth mentioning again. We cannot underestimate the significant importance of having Andy Campbell on board. A man who is one of the most respected and influential people in his field doesn't mess around with micro cap businesses unless there is a bloody good reason to do so !

Nick241213 May '26 - 18:20 - 4566 of 4568

3 0

I thought I would look at the base case valuation for RUA as of today. Bear in mind it's on the extreme side of conservative. It highlights that RUA is still in bargain basement territory given it comes out at between 45p to 53p - that's broadly in line with Cavendish's 50p

Structural Heart stake: about £7m

This reflects the current funded spinout/early-stage value rather than any major clinical-ready upside. Cavendish says the £3m funding should take the mitral valve programme to first-in-human readiness, but at this base stage I am not pricing in that success.

Cash: about £3.2m

RUA Medical Devices/CDMO: about £13m–£16m

Current revenue is around £5.2m. On a conservative 2.5x–3x revenue multiple, that gives roughly £13m–£16m. It’s an overly conservative base case so I have not included the additional anticipated £5m future extra annual revenue from contracts to come as flagged up by the trading update.

RUA Biomaterials: about £5m–£7m

If current royalties are around £700k at roughly 90% margin, that implies c. £630k high-margin profit. A conservative 8x–10x profit multiple gives £5m–£6.3m, with a little allowance for the new contract/audit upside. That’s again extremely conservative given we’ve been told (Hybridan note) current revenues from this source “barely scratch the surface” for “in progress” new licensing opportunities.

So base case valuation:

Structural Heart: £7m

Cash: £3.25m

CDMO: £13m–£16m

Biomaterials: £5m–£7m

Total base valuation: about £28m–£33m.

With around 62m shares in issue, that equates to roughly:

45p–53p per share.

So interestingly, an overly conservative base case (particularly for CDMO) already supports Cavendish’s 50p target, without needing to assume a significant revaluation of Structural Heart yet. Neither does it factor in any additional revenues for CDMO of which a significant amount, if not all, is pretty much nailed on. The £5m extra revenues are of course based on just 60% of current products in development transitioning to multi-year commercial product manufacturing contracts. As noted in the research notes, these are for products that already have regulatory approval or are close to achieving that status.

Que

Que

Not even 20 shares

I'm with you here...